MetaCap

Bambusa Therapeutics (BBTX) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $697.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%SLDB+0.81%
+24%+10%-5%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%SLDB+0.81%
+11%+5%-1%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus SLDB key metrics
MetricBBTXSLDB
Share price$16.00$6.25
Market cap$815.08M$697.57M
1-day change+2.89%-2.95%
YTD return—+10.82%
1-year return—+32.98%
5-year return—-77.78%
EPS (TTM)$-1.73$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-174.32M
52-week high$17.65$11.45
52-week low$13.60$4.65
Distance from 52-week high-9.35%-45.41%
Analyst consensus—strong_buy
Avg. price target upside—+199.36%
Average volume359.41K1.30M
Shares outstanding50.94M111.61M
Employees26121
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

BBTX vs SLDB FAQ

Which is bigger, Bambusa Therapeutics or Solid Biosciences?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $697.57M for Solid Biosciences (SLDB).

Are Bambusa Therapeutics and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons